Storia in 4 fonti

ASCO26: In vivo oncology approaches continue to show promise

Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.

Raccontata da

pharmaceutical-technology.com

statnews.com

endpoints.news

biopharmadive.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

endpoints.news3 mesi fa

ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma

ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries

Leggi questa versione → originale

pharmaceutical-technology.com

Timeline cronologica

lunedì 1 giugno 2026·pharmaceutical-technology.com
ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.
lunedì 1 giugno 2026·pharmaceutical-technology.com
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

3 mesi fa

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical…

Akeso's ivonescimab bispecific achieved 34% death risk reduction in squamous NSCLC; Eli Lilly expanded Retevmo (RET TKI) to adjuvant early-stage disease. Both mark competitive reshaping of NSCLC, with Idafang projected at $11bn global sales by 2032.

Leggi questa versione → originale

biopharmadive.com3 mesi fa

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

Leggi questa versione → originale

statnews.com3 mesi fa

A turning point for pancreatic cancer patients

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

Leggi questa versione → originale

lunedì 1 giugno 2026·

statnews.com

A turning point for pancreatic cancer patients

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

lunedì 1 giugno 2026·

pharmaceutical-technology.com

ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.

lunedì 1 giugno 2026·

endpoints.news

ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma

ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries

martedì 2 giugno 2026·

biopharmadive.com

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

martedì 2 giugno 2026·

pharmaceutical-technology.com